Purpose: Diabetes profoundly and negatively impacts all domains of female sexual function, however, the underlying pathophysiological mechanisms remain unknown. To date, limited studies have been published on the effects of type 1 & type 2 diabetes on female genital sexual arousal and how this may impact overall sexual function. The aim of this review is to discuss the effects of diabetes on female sexual function and insights from laboratory studies on the underlying pathophysiology. Materials and Methods: Using PubMed, we reviewed and evaluated the literature published between 1970 and 2009 and data from our laboratories and others investigating the effects of type 1 and type 2 diabetes on genital sexual arousal responses. Results: Women with diabetes experience diminished genital arousal, reduced vaginal lubrication, vaginal atrophy, dyspareunia, and increased vaginal infections. Also, a number of studies using type 1 and type 2 diabetic animal models have reported reduced plasma estradiol levels and marked physiological, biochemical and histological changes in genital tissues. In animal studies, diabetes alters genital tissue structure and attenuates expression of the estrogen, progesterone and androgen receptors and alters vaginal and clitoral hemodynamics. Importantly, treatment of diabetic animals with estradiol in the face of persistent hyperglycemia can restore vaginal structure and sex steroid receptor expression. Conclusions: Type 1 & type 2 diabetic complications produce significant structural and functional disruptions in genital organs and attenuate genital hemodynamics. In the type 2 animal model, estradiol treatment ameliorates diabetic-induced pathophysiological alterations in genital tissues, such as the vagina. This suggests that estrogen supplementation may be beneficial in restoring diabetes-induced genital pathology. (Korean J Urol 2009;50:211-223)
INTRODUCTION
The effects of diabetes on women's sexual health have received limited attention. [1] [2] [3] In 1971, Kolodny 4 first suggested a possible link between women's sexual dysfunction and diabetes.
Although the effects of diabetes are well known to contribute to erectile dysfunction, 5 relatively limited clinical epidemiological studies have addressed the etiology of sexual dysfunction in women. Some reports, however, point to similar deleterious effects of diabetes on female sexual function. Diabetes causes vasculopathies, neuropathies, and increases the likelihood of vaginal infections, all of which are integral to sexual health. [6] [7] [8] Accumulating evidence strongly suggests that diabetes has a profound impact on female sexual function and well being.
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Jovanovic 12 pointed to the considerable disparity that existed in efforts dedicated to studies of diabetes on male versus female sexual dysfunction. He noted that between 1997 to 2002, approximately 1,983 articles were published on diabetes and male sexual dysfunction, compared to only 13 articles published on diabetes and female sexual dysfunction. This illustrates the urgent need for more research in this field.
Clinical and epidemiological studies
The estimated prevalence of sexual dysfunction in diabetic women varies between 14-51%. 1, 2 Approximately 27% of type 1 diabetic women experienced sexual dysfunctions compared to 15% of control subjects, with a significant number of women complaining of decreased lubrication. 1, 2 In addition, the prevalence of sexual dysfunctions was reported to be consistently higher in type 2 diabetic women with a higher incidence of decreased libido (77%), compared to control subjects (20%). 13 Symptoms most commonly reported by diabetic women included loss of libido, diminished clitoral sensitivity, decreased vaginal lubrication, and increased vaginal discomfort. 2, [13] [14] [15] [16] [17] More recently, Doruk et al, 18 reported an increased incidence of sexual dysfunctions including diminished arousal in type 2 diabetic patients and decreased arousal, lubrication and orgasm in type 1 diabetic women. In a recent study by Abu Ali et al, 19 diabetic women aged 50 years or older were reported to have a significantly higher prevalence of decreased sexual desire than their nondiabetic age-matched counterparts (79.5% vs. 59%). Depression was also reported to be a predictor of decreased desire in diabetic women. 20 Fatemi and Taghavi 21 reported that sexual drive, arousal, vaginal lubrication, orgasm and overall satisfaction in Iranian women were all significantly lower in diabetic women, as assessed by sexual function questionnaires. Similar findings were reported in Nigerian 22 and Peruvian women. 23 The prevalence rate for orgasmic disorders in diabetic women has been estimated to be between 11-35%. 4, 15, 16 The type of diabetes may also have an impact on the incidence of orgasmic disorder. Schreiner-Engel 16 showed that type 1 diabetic women did not report reduced frequency of orgasm, whereas type 2 diabetic women reported significantly less frequent orgasms when compared to control subjects. Similarly, Enzlin et al 2 found that type 1 diabetic women, both with and without diabetic complications, did not report problems with orgasm.
In contrast, Doruk et al, 18 reported no significant differences with regard to orgasm in type 2 diabetic women, whereas orgasm was significantly reduced in type 1 diabetic women when compared to healthy, control subjects. These limited and conflicting studies suggest that sexual orgasmic disorder is frequent in diabetic women, but that the type (and potentially, duration)
of diabetes may have a differential impact on sexual function.
Dyspareunia is the most common form of sexual pain disorder in women and its estimated prevalence rate varies between 3-16% in the diabetic population. 4, 16, 20, 24, 25 
EFFECTS OF DIABETES ON FEMALE
GENITAL SEXUAL AROUSAL
Circulating plasma estradiol and testosteorne levels
A number of studies have reported histologic and/or physiologic changes in genital tissues of type 1 diabetic animals. [34] [35] [36] Interestingly, diabetic animals had reduced plasma estradiol lev- Fig. 1 . Plasma estradiol and testosterone levels in control and diabetic mice. Plasma levels of estradiol and testosterone from control, diabetic (untreated) and diabetic animals treated with estradiol (E2) were determined by immunoassay at the Endocrinology Laboratory, Animal Health Diagnostic Center at the Cornell University College of Veterinary Medicine (Ithaca, USA), as described by Cushman et al. 47, 57 Note, that estradiol levels decreased in diabetic animals and testosterone levels increased in diabetic animals. This resulted in an imbalance in the testosterone to estradiol ratio (T/E) in diabetic animals. This ratio is normalized in diabetic animals treated with estradiol. els and increased testosterone levels. [36] [37] [38] [39] Similarly, studies suggest that type 2 diabetes reduces circulating estradiol levels. [38] [39] [40] [41] Further, data from our laboratory have demonstrated that type 2 diabetic female mice have reduced estradiol levels and increased testosterone levels with testosterone to estradiol ratio higher in the diabetic animals than in control or estrogen treated diabetic animals (Fig. 1) . Reduced estradiol levels were consistent with marked uterine and vaginal atrophy in untreated diabetic animals.
Ovarian aromatase activity has been shown to be insulindependent [42] [43] [44] Recent studies from our laboratory have shown that type 2 diabetic animals also exhibited dramatic alterations in vaginal histo-architecture (Fig. 3) . 47 The vaginal wall appeared significantly thinner and the epithelium was markedly atrophic and resembled that of estrogen-deficient animals. Furthermore, the has been shown to disrupt cell growth and proliferation and induce apoptosis in the pancreas, 38 heart, 48 kidney, 49 retina, 50 and spinal cord. 51 The vaginal epithelium has important functions in vaginal lubrication (e.g., permeability and the production of mucin glycoproteins), thought to be regulated by estrogens. 52 The existence Normal stratification of the epithelium protects the vaginal wall from abrasions and trauma during coitus. Thus, in the diabetic state, the loss or decrease of the physical barrier between the epithelium and underlying lamina propria where the sensory nerve fibers lie, may account for painful vaginal sensations experienced in diabetic patients. 13, 16 In addition, the superficial stratified layers of the epithelium impose a physical barrier to bacteria and fungi that richly populate the vaginal lumen.
Glycogen within the superficial epithelial cells is broken down to produce lactic acid in order to maintain an acidic environment that suppresses bacterial and fungal infections. Human studies have shown that diabetic patients are at a higher risk for developing vaginal candidiasis. 
Sex steroid receptor expression
Estrogen receptor alpha (ERα) protein expression is significantly reduced in vaginal tissues from type 1 diabetic animals. In the vagina of type 2 diabetic animals, overall expression of ERα, PR and AR was markedly reduced and significant changes in receptor localization and distribution was also noted. Formalin-fixed and paraffin-embedded vaginal tissue sections from control (A) and untreated diabetic (B) animals were subjected to immunostaining procedures using anti-nNOS antibody and counterstained with Gill's hematoxylin (scale bar represents 100μm, panels are at magnification, x200). nNOS immunopositive nerve fibers are denoted by arrowheads. E: epithelium, LP: lamina propria, M: muscularis.
Fig. 5. Effects of type 2 diabetes and estradiol supplementation on the density of neural nitric oxide synthase (nNOS) immunopositive nerve fibers in vaginal tissue sections. Formalin-fixed and paraffin-embedded vaginal tissue sections from control (A), untreated diabetic (B)
, and estradiol treated diabetic (C) animals were subjected to immunostaining procedures using anti-nNOS antibody and counterstained with Gill's hematoxylin (scale bar represents 20μm, panels are at magnification, x400). nNOS immunopositive nerve fibers are denoted by arrowheads.
Nitric oxide, smooth muscle function, and genital hemodynamics
Sexual arousal in the female is mediated by a host of physiological mechanisms including vascular smooth muscle relaxation via nitrergic neurotransmission which leads to increased vaginal blood flow and lubrication. 26, 28, 58 The nitrergic neuronal subsystem plays an important role, not only in vasodilation, but also in the relaxation of the non-vascular smooth muscle of genital tissues. 27, 28, 59, 60 Immunostaining for neural nitric oxide synthase (nNOS) revealed that the nitrergic system of nerve fibers was significantly attenuated in type 1 & type 2 diabetic animals ( Fig. 4, 5 ). When changes in the thickness of the vaginal wall due to diabetes are taken into account, the total extent of nitrergic innervation was drastically reduced in type 1 diabetic animals (Fig. 2, unpublished data) . A significant reduction of the nitrergic population of nerve fibers was noted in vaginal tissue of type 2 diabetic animals (Fig. 5) . 57 When changes in the thickness of the vaginal wall are taken into account, the total extent of nitrergic innervation was drastically reduced in these diabetic animals. These findings were in accordance of Giraldi et al 58, 61 who reported significant attenuation in the ni- 67 Endothelial dysfunction, a possible early manifestation of atherogenesis, was more prominent in postmenopausal diabetic patients when compared to normal postmenopausal subjects. 68 The incidence and rate of progression of renal disease were also shown to be far greater in nondiabetic men than nondiabetic women, further suggesting a protective role for estrogens. 69 Moreover, premenopausal diabetic women have a lower risk of developing end-stage renal disease compared with age-matched diabetic males, whereas this protection is lost after menopause. 70 Thus, these clinical studies strongly suggest a potential link between estrogens and progression of diabetic induced pathophysiology of estrogen-dependent tissues. Based on clinical and pre-clinical evidence, we advance the hypothesis that diabetes disrupts estrogen biosynthesis, estrogen receptor expression and function (Fig. 6) .
POTENTIAL DISRUPTION OF ESTROGEN ACTION IN DIABETES
If, as hypothesized above, estrogen decline is indeed indicated in the progression of diabetic disease, then estrogen replacement may reverse or restore diabetes-induced pathology.
Interestingly, estrogen therapy has proven to be protective in a number of human and animal studies. Treatment of diabetic animals with 17β-estradiol attenuated diabetic nephropathy by reducing albuminuria, improving creatinine clearance, reducing glomerulosclerosis, tubulointerstitial fibrosis, and reducing TGF-β1expression in the renal cortex. 71 In a group of healthy, nonobese postmenopausal women, transdermal 17β-estradiol users experienced a significant reduction in the incidence of type 2 diabetes when compared to "nonhormone users". 72 In 38 reported that diabetes-induced hypercytolipidemia in pancreatic islet cells was markedly reduced following estrogen treatment along with the restoration of β -cell cytoarchitecture and cellular insulin concentrations.
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Low-dose estradiol treatment of postmenopausal women with type 2 diabetes significantly lowered fasting glucose and total cholesterol when compared to placebo treated postmenopausal women with type 2 diabetes. 73 Therefore, studies suggest a protective and possible anti-diabetogenic role for estrogen therapy in women. protein expression. 74 In addition, uterine arteries treated with 17-beta estradiol exhibited an increase in vascular smooth muscle nNOS mRNA protein expression. 75 Thus, the data in our study 57 suggests that treatment of diabetic animals with estradiol enhanced the density of nNOS immunopositive fibers.
ESTRADIOL SUPPLEMENTATION AMELIORATES DIABETES-INDUCED VAGINAL PATHOLOGIES
These findings implicate a functional role of estradiol in maintaining nNOS expression and the relaxant properties of the vascular and nonvascular smooth muscle of the vaginal wall.
We further observed that estradiol supplementation restored steroid hormone immunolocalization in the vagina in a differential manner. 47 This finding suggests disruption of estrogen signaling in diabetes. This comes from several lines of evidence that include the dramatic changes in vaginal tissue structure, as well as the coincident changes in the levels of PR and AR. As described previously, vaginal tissue from type 1 and/or type 2 diabetic mice exhibited marked reductions of epithelial thick-ness and muscularis area whereas these diabetes-induced changes were ameliorated by estradiol supplementation. These atrophic changes observed in intact diabetic mice paralleled the structural alterations observed in ovariectomized rats. 29, 30 In addition, PR and AR expression has been shown to be regulated by the activity of ERα. Indeed, regulation of the progesterone receptor has been shown to be tightly coupled to estrogen signaling. In ovariectomized animals, estradiol treatment has been shown to increase PR in vaginal epithelial cells via ERα signaling. 76 Similar studies have also reported PR expression levels to decrease after ovariectomy and be restored with estradiol treatment. 29, 30, 77, 78 Thus, increased PR expression in type 2 diabetic animals by estradiol supplementation strongly suggests restoration of estrogen receptor signaling.
With respect to the AR, its actions have also been shown to be regulated by estradiol. Pelletier et al 79 have shown that ovariectomy decreases AR mRNA levels in the mouse uterus and vagina, while estradiol treatment restores AR expression to levels observed in control animals, suggesting a positive estrogenic regulation of AR in these tissues. 79, 80 Furthermore, it has been demonstrated in ovariectomized animals that AR levels were reduced in the proximal and distal vagina, whereas expression was restored in estrogen-treated animals. 81 The decreased levels of androgen receptor in the type 1 and type 2 diabetic animals suggest that estrogen action may be disrupted in the diabetic state. Therefore, estrogenic restoration of AR expression and distribution also suggests re-establishment of estrogen receptor signaling in diabetic animals.
Our findings are in agreement with previous studies that have correlated changes in steroid hormone receptors with the diabetic state. Ekka et al 76 showed similar estrogen-induced progesterone receptor expression in uterine tissues in a type 1 diabetic rat animal model. 76 Interestingly in our studies, 47, 57 estrogen supplementation (at supraphysiologic levels), in diabetic animals, down-regulated ERα expression beyond levels detected in untreated diabetic animals. However, this observation is also consistent with studies in female rats in which estradiol treatment of ovariectomized animals down-regulated ERα in vaginal tissues. 29, 30 Thus, the data from the present study suggests that types 1 and 2 diabetes decreased the expression of ERα as well as PR and AR in the vagina. The changes in steroid receptor expression, therefore, may underlie the observed diabetes-induced changes in the structural integrity of the vagina.
POTENTIAL MECHANISMS INVOLVED IN ESTRADIOL RESTORATION OF DIABETES-INDUCED CHANGES IN THE VAGINA
Evidence for a role of estradiol in energy metabolism and glucose homeostasis has been suggested by several human and animal studies. [82] [83] [84] [85] The exact cellular mechanisms involved in estradiol-mediated glucose metabolism remain to be elucidated.
One possible mechanism is ERα regulation of the expression of glucose transporters. Several studies have suggested a possible link between estradiol and the expression of GLUT4. 86, 87 GLUT4 expression has been shown to be upregulated with estrogen treatment in primate cerebral cortex. 88 ERα null mice showed reduced GLUT4 expression in skeletal muscle. 86, 87 Changes in GLUT4 expression and/or translocation to the plasma membrane may result in insulin resistance. 86, 87 Selective estrogen receptor modulators (SERMs) increase GLUT3 and GLUT4 mRNA expression levels in cerebral cortical neurons and may possess neuroprotective effects due to increased glucose transport. 88 It is therefore possible that decreased estradiol levels and down regulation of ERα in the untreated diabetic (db/db) mice may contribute to a dysregulation of GLUT4 expression and consequently lead to altered glucose uptake at the level of insulin-sensitive tissues. This, however, remains to be established.
Studies in animal models of diabetic nephropathy suggest that estrogen regulates diabetes-induced fibrosis. Supplementation with 17β-estradiol attenuated diabetic renal disease by regulating extracellular matrix protein expression associated with glomerulosclerosis and tubulointerstitial fibrosis, TGF-β and its downstream regulatory proteins, and the activity of matrix metalloproteinases in renal tissues. 40, 89 17β-estradiol also suppresses renal mesangial expansion and fibronectin accumulation in diabetic db/db mice. 55 Furthermore, ERα knockout mice exhibited proteinuria and glomerulonephritis suggesting a protective role for estrogen and its actions on renal tissues. 90 Thus, these studies support a role for estradiol in ameliorating diabetes-induced fibrotic pathology. 
